There may be multiple problems that can be faced by any organization. Moreover, it also helps to the extent to which change is useful for the company and also guide the direction for the change.
Challenges remain in eliminating onchocerciasis in the two remaining areas with active transmission. Activities that can be determined as your weakness in the market. Percentage of research budget that Merck should invest in drugs that will produce a substandard return on investment As a company that produces drugs to cure diseases in both humans and animals, Merck operates in a complex dynamic that requires it to take decisions that may not lead to profitability.
Unique resources and low cost resources company have. The laboratory work at UVG has been done in close coordination with The Carter Center and the University of South Florida, critical collaborators in the elimination effort in the Americas.
Analysis Based on Ethical Theories Cultural relativism means that any decision is right or wrong depending on whose side you are taking at the moment.
Part of the culture at Merck is one of giving back to the community and helping others so for Merck, the decision to develop invermectin was an easy one. In the strengths, management should identify the following points exists in the organization: There are no recommendations I could make for Merck in the way they handle these situations.
Backlash forces investors to pull out. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. The company also has an obligation to the scientists to provide the resources needed to continue their research.
N FDA has not classified the drug. Some dog breeds especially the Rough Colliethe Smooth Colliethe Shetland Sheepdogand the Australian Shepherdthough, have a high incidence of a certain mutation within the MDR1 gene coding for P-glycoprotein ; affected animals are particularly sensitive to the toxic effects of ivermectin.
Change in Legislation and taxation effects on the company Trend of regulations and deregulations. The morally right decision would be to invest in the research, ignoring the possibility of lost profits.
The qualm to this is that, the consumers of the drug could not pay for the medication. In addition, it also identifies the weaknesses of the organization that will help to be eliminated and manage the threats that would catch the attention of the management.
References Ethics and transparency.
Alcohol Interacts with Alcohol. Standards of health, education and social mobility levels. Opportunities for Merck And River Blindness can be obtained from things such as: SWOT analysis helps the business to identify its strengths and weaknesses, as well as understanding of opportunity that can be availed and the threat that the company is facing.
While accepting the responsibility of continuing research into this disease was admirable, Merck and Co. Stakeholder Analysis The key stakeholders are the investors, the scientists, the consumers, and the company in general. Merck and Co., River Blindness Ethical Case Analysis Lennard de Jong Excelsior College Author Note This paper was prepared for Business Ethics, Ethical Case.
Merck and Co., River Blindness Ethical Case Analysis Lennard de Jong Excelsior College Author Note This paper was prepared for Business Ethics, Ethical Case Analysis, taught by Dr.
Moser. Merck and River Blindness Onchocerciasis, known as river blindness, is caused by parasitic worms that live in the small black flies that breed in and about fast-moving rivers in developing countries in the Middle East, Africa, and Latin America.
This could help them build a strong brand equity, goodwill and reputation in the long run thereby creating a foundation for profitability in future. For instance, I believe that Merck has a social responsibility and a moral obligation to invest heavily in the cure for River blindness.
Merck and River Blindness Essay Merck and River Blindness (Onchocerciasis) In understanding the decision Merck made to donate medicines, we need to start by understanding the motivations and core values behind the company that undertook the actions.
In this case, river blindness disease was a very serious problem, and Dr. Vagelos was the one who could make a decision as to whether the research and development of a human version of ivermectin should be carried on, then it was his responsibility to pursue it.Brand and river blindness